SkylineDx, Researchers

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma

25.07.2017 - 15:02:30

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma. SkylineDx Austria Belgium Czech Republic Denmark Finland France Germany Greece Ireland Italy Luxembourg Netherlands Norway Poland Portugal Russia Spain Sweden Switzerland United Kingdom California

1 van Beers EH, van Vliet M, Kuiper R, et al. Prognostic validation of SKY92 and its combination with ISS in an independent cohort of Multiple Myeloma patients. Clin Lymphoma Myeloma Leuk. 2017. doi: 10.1016/j.clml.2017.06.020.
2 International Staging System. Multiple Myeloma Research Foundation. 2017. https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/international-staging-system/. Accessed July 10, 2017.
3 Kuiper R, van Duin M, van Vliet, MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126(17):1996-2004.
4 Broijl A, Kuiper R, van Duin M, et al. Hoog- en laagrisico-multipel myeloom kunnen worden voorspeld met de combinatie van EMC92 en ISS. Dutch J Hematol. 2017;11:339-40.
5 van Beers EH, van Vliet M, de Best L, et al. SKY92 GEP, iFISH, and ISS comparisons for risk stratification in multiple myeloma. Poster p661 presented at 20th European Hematology Association Congress, Vienna, Austria, June 13, 2015.  

@ prnewswire.co.uk

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!